Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis.
In cardiac transplantation, chronic rejection takes the form of an occlusive vasculopathy. The mechanism underlying this disorder remains unclear. The purpose of this study was to investigate the role nitric oxide (NO) may play in the development of allograft arteriosclerosis. Rat aortic allografts from ACI donors to Wistar Furth recipients with a strong genetic disparity in both major and minor histocompatibility antigens were used for transplantation. Allografts collected at 28 d were found to have significant increases in both inducible NO synthase (iNOS) mRNA and protein as well as in intimal thickness when compared with isografts. Inhibiting NO production with an iNOS inhibitor increased the intimal thickening by 57.2%, indicating that NO suppresses the development of allograft arteriosclerosis. Next, we evaluated the effect of cyclosporine (CsA) on iNOS expression and allograft arteriosclerosis. CsA (10 mg/kg/d) suppressed the expression of iNOS in response to balloon-induced aortic injury. Similarly, CsA inhibited iNOS expression in the aortic allografts, associated with a 65% increase in intimal thickening. Finally, we investigated the effect of adenoviral-mediated iNOS gene transfer on allograft arteriosclerosis. Transduction with iNOS using an adenoviral vector suppressed completely the development of allograft arteriosclerosis in both untreated recipients and recipients treated with CsA. These results suggest that the early immune-mediated upregulation in iNOS expression partially protects aortic allografts from the development of allograft arteriosclerosis, and that iNOS gene transfer strategies may prove useful in preventing the development of this otherwise untreatable disease process.
Shears
L L
LL
Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA.
Kawaharada
N
N
Tzeng
E
E
Billiar
T R
TR
Watkins
S C
SC
Kovesdi
I
I
Lizonova
A
A
Pham
S M
SM
D000818:Animals; D001011:Aorta / Q000637:transplantation*; D001161:Arteriosclerosis / Q000517:prevention & control*; D016572:Cyclosporine / Q000494:pharmacology; D015316:Genetic Therapy / Q000379:methods; D006084:Graft Rejection / Q000276:immunology*; D006649:Histocompatibility Antigens / Q000235:genetics; D006965:Hyperplasia; D007166:Immunosuppressive Agents / Q000494:pharmacology; D009569:Nitric Oxide / Q000494:pharmacology*; D019001:Nitric Oxide Synthase / Q000378:metabolism*; D016377:Organ Transplantation / Q000009:adverse effects*; D051381:Rats; D017208:Rats, Wistar; D014184:Transplantation, Homologous; D017539:Tunica Intima / Q000473:pathology
D006649:Histocompatibility Antigens; D007166:Immunosuppressive Agents; D009569:Nitric Oxide; D016572:Cyclosporine; D019001:Nitric Oxide Synthase